Drug Pricing

Commentary

Don’t Legislate Away Biopharmaceutical Innovation

The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
Commentary

The FDA’s Bad Medicine

Before leaving office, former Food and Drug Administration Commissioner Scott Gottlieb told the Senate Appropriations Committee that Congress should create a new requirement for opioid approvals. New opioids should have to demonstrate superiority over those already on the market, he said. That would be a departure from the current statutory ...
Drug Importation

Sally Pipes in Healthline Story on Prescription Drugs and Canada

Why People with Diabetes Drive for Hours to Buy Insulin in Canada By Christopher Curley For Lija Greenseid, the math was simple. Drive a few hours to pay $56 for a box of Humalog insulin pens for her young daughter with type 1 diabetes or pay as much as $230 ...
Commentary

Price Controls by Another Name

The costs of medicines continue to dominate the headlines, attracting the attention of Congress and the Trump Administration. Reforms are necessary, but many of the reforms under consideration will make the situation worse. Indexing U.S. prices to the prices in other countries that use price controls, or using third-party arbitration ...
Commentary

Say No To Canadian Drug Imports

Lawmakers in the Sunshine State are looking to our northern neighbor to help them reduce drug prices. The Florida House of Representatives recently passed a bill that would allow the importation and sale of prescription drugs from Canada, where prices are generally lower because the government forcibly controls them. Florida isn’t the ...
Business & Economics

Price Controls Are Never The Answer

Senator Rick Scott (R-FL) has just doubled down on one of the Trump Administration’s unsound ideas. His proposal is disappointing for many reasons, particularly because Alex Azar, Secretary of Health and Human Services, has proposed an alternative reform that, if Congress implemented, would meaningfully improve the affordability of prescription drugs ...
Commentary

The FDA has problems — Here are the qualities the next commissioner must have to fix them

The Food and Drug Administration (FDA) is the nation’s most ubiquitous regulatory agency.  It oversees a vast array of medical and food products that account for 25 cents of every consumer dollar, with a value of over a trillion dollars annually. And the agency has problems. It’s too risk-averse, bureaucratically ...
Commentary

Governor’s health care proposal puts politics before patients

In California, politics is taking precedence over patients. That’s the only conclusion to draw from Gov. Gavin Newsom’s recently released health care plan. He’s looking to impose price controls on prescription drugs. He’d like to expand Medicaid to undocumented immigrants up to the age of 26. He’s called for re-imposing ...
Commentary

Drug price controls will stifle innovation: Pharmaceutical industry R&D is saving lives

This year, 1.7 million Americans will be diagnosed with cancer. For over 600,000 of them, that diagnosis will prove fatal. But there’s hope on the horizon. More Americans are surviving cancer each year, according to a new study from the American Cancer Society. The cancer death rate declined precipitously between ...
Business & Economics

Fostering Transparency In The Pharmaceutical Market

In response to the problem of rising list prices for drugs, elected officials continue to propose counterproductive reforms. Whether it is importing drugs from Canada or indexing U.S. drug prices to the prices charged in other countries, these policies will make the current bad situation worse because they fail to ...
Commentary

Don’t Legislate Away Biopharmaceutical Innovation

The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
Commentary

The FDA’s Bad Medicine

Before leaving office, former Food and Drug Administration Commissioner Scott Gottlieb told the Senate Appropriations Committee that Congress should create a new requirement for opioid approvals. New opioids should have to demonstrate superiority over those already on the market, he said. That would be a departure from the current statutory ...
Drug Importation

Sally Pipes in Healthline Story on Prescription Drugs and Canada

Why People with Diabetes Drive for Hours to Buy Insulin in Canada By Christopher Curley For Lija Greenseid, the math was simple. Drive a few hours to pay $56 for a box of Humalog insulin pens for her young daughter with type 1 diabetes or pay as much as $230 ...
Commentary

Price Controls by Another Name

The costs of medicines continue to dominate the headlines, attracting the attention of Congress and the Trump Administration. Reforms are necessary, but many of the reforms under consideration will make the situation worse. Indexing U.S. prices to the prices in other countries that use price controls, or using third-party arbitration ...
Commentary

Say No To Canadian Drug Imports

Lawmakers in the Sunshine State are looking to our northern neighbor to help them reduce drug prices. The Florida House of Representatives recently passed a bill that would allow the importation and sale of prescription drugs from Canada, where prices are generally lower because the government forcibly controls them. Florida isn’t the ...
Business & Economics

Price Controls Are Never The Answer

Senator Rick Scott (R-FL) has just doubled down on one of the Trump Administration’s unsound ideas. His proposal is disappointing for many reasons, particularly because Alex Azar, Secretary of Health and Human Services, has proposed an alternative reform that, if Congress implemented, would meaningfully improve the affordability of prescription drugs ...
Commentary

The FDA has problems — Here are the qualities the next commissioner must have to fix them

The Food and Drug Administration (FDA) is the nation’s most ubiquitous regulatory agency.  It oversees a vast array of medical and food products that account for 25 cents of every consumer dollar, with a value of over a trillion dollars annually. And the agency has problems. It’s too risk-averse, bureaucratically ...
Commentary

Governor’s health care proposal puts politics before patients

In California, politics is taking precedence over patients. That’s the only conclusion to draw from Gov. Gavin Newsom’s recently released health care plan. He’s looking to impose price controls on prescription drugs. He’d like to expand Medicaid to undocumented immigrants up to the age of 26. He’s called for re-imposing ...
Commentary

Drug price controls will stifle innovation: Pharmaceutical industry R&D is saving lives

This year, 1.7 million Americans will be diagnosed with cancer. For over 600,000 of them, that diagnosis will prove fatal. But there’s hope on the horizon. More Americans are surviving cancer each year, according to a new study from the American Cancer Society. The cancer death rate declined precipitously between ...
Business & Economics

Fostering Transparency In The Pharmaceutical Market

In response to the problem of rising list prices for drugs, elected officials continue to propose counterproductive reforms. Whether it is importing drugs from Canada or indexing U.S. drug prices to the prices charged in other countries, these policies will make the current bad situation worse because they fail to ...
Scroll to Top